Saturday, 19.09.2026, Calendar Week 38, 262nd day of the year, 103 days remaining until EoY.

Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.

The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US98937L1052

Reset filter

Do you already know our new terminal view? Click here.

FIGI: BBG01J1MG9D6

ZBIO

Zenas BioPharma, Inc.

GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH

NAME

Zenas BioPharma, Inc.

ISIN

US98937L1052

TICKER

ZBIO

MIC

XNAS

REUTERS

ZBIO.OQ

BLOOMBERG

ZBIO US

Thu, 08.05.2025 Zenas BioPharma

Newsfeed

Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) Seeking Recovery for Investors - Contact The Gross Law Firm | Zenas BioPharma, Inc.

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm | Zenas BioPharma, Inc.

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma | Zenas BioPharma, Inc.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO | Zenas BioPharma, Inc.

Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO | Zenas BioPharma, Inc.

The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline | Zenas BioPharma, Inc.

The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline | Zenas BioPharma, Inc.

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm | Zenas BioPharma, Inc.

Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO | Zenas BioPharma, Inc.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO | Zenas BioPharma, Inc.

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit | Zenas BioPharma, Inc.

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm | Zenas BioPharma, Inc.

Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO | Zenas BioPharma, Inc.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc.(ZBIO) Shareholders | Zenas BioPharma, Inc.

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm | Zenas BioPharma, Inc.

The Gross Law Firm Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ZBIO | Zenas BioPharma, Inc.

ZBIO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit | Zenas BioPharma, Inc.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO | Zenas BioPharma, Inc.

Contact Levi & Korsinsky by June 16, 2025 Deadline to Join Class Action Against Zenas BioPharma, Inc.(ZBIO) | Zenas BioPharma, Inc.

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm | Zenas BioPharma, Inc.

ZBIO INVESTOR NOTICE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit | Zenas BioPharma, Inc.

Shareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO | Zenas BioPharma, Inc.

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit | Zenas BioPharma, Inc.

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Zenas BioPharma, Inc.

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma | Zenas BioPharma, Inc.

ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit | Zenas BioPharma, Inc.

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm | Zenas BioPharma, Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Zenas BioPharma, Inc. – ZBIO | Zenas BioPharma, Inc.

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer | Zenas BioPharma, Inc.

Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation – ZBIO | Zenas BioPharma, Inc.

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer | Zenas BioPharma, Inc.

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases | Zenas BioPharma, Inc.

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference | Zenas BioPharma, Inc.

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | Zenas BioPharma, Inc.

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | Zenas BioPharma, Inc.